Skip to content
TrialScanner

NCT02174432

Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

Phase 2/Phase 3CompletedTRVILead

Registry record

Lead sponsor
Trevi Therapeutics
Conditions
Prurigo Nodularis; Nodularis Prurigo; Prurigo
Primary completion
Sep 3, 2017Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02174432 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02174432: Open Label Extension Study... | TrialScanner